Zymeworks, Merck partner to develop bi-specific antibody therapeutics
As per the agreement Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies toward certain exclusive therapeutic targets. Zymeworks will receive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.